Living meta-analysis and evidence synthesis of therapies for COVID-19

 

• COVID 19 hospitalized
• COVID 19 all comers
• COVID-19 mild to moderate
• COVID-19 severe or critically
• COVID 19 outpatients
• COVID-19 (hospitalized or not)
• COVID-19 prophylaxis (children)
• COVID-19 prophylaxis (excluding children)
• infections other than COVID-19
• Long COVID-19
• preventing respiratory virus transmission
• secondary prevention

 

• vaccines
• Inactivated virus vaccine
• Covaxin, Bharat Biotech (BBV152)
• Sinopharm Beijing (BBIBP-CorV)
• mRNA vaccine
• Comirnaty (tozinameran - Pfizer/BIONTECH)
• Spikevax (Moderna mRNA-1273 COVID-19 vaccine)
• Non replicating viral vector
• Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)
• protein subunit vaccine
• Nuvaxovid (NVX-CoV2373) Novavax
• All treatment (not recommended)

    Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS) see more...